Q2 2017 Earnings Forecast for AngioDynamics Inc. Issued By KeyCorp (ANGO)
AngioDynamics Inc. (NASDAQ:ANGO) – Analysts at KeyCorp lifted their Q2 2017 earnings per share estimates for shares of AngioDynamics in a note issued to investors on Wednesday. KeyCorp analyst M. Mishan now forecasts that the brokerage will post earnings of $0.17 per share for the quarter, up from their previous estimate of $0.16. KeyCorp has a “Buy” rating and a $18.00 price objective on the stock. KeyCorp also issued estimates for AngioDynamics’ Q3 2017 earnings at $0.13 EPS and Q4 2017 earnings at $0.18 EPS.
Separately, Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $15.20.
AngioDynamics (NASDAQ:ANGO) traded up 2.25% on Thursday, reaching $16.84. The company’s stock had a trading volume of 318,798 shares. AngioDynamics has a 1-year low of $9.71 and a 1-year high of $17.64. The company’s market capitalization is $613.35 million. The firm’s 50 day moving average price is $16.78 and its 200-day moving average price is $14.27.
AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, October 5th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. AngioDynamics had a positive return on equity of 3.94% and a negative net margin of 12.57%. The company had revenue of $88.10 million for the quarter. During the same period in the prior year, the company posted $0.11 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Prudential Financial Inc. increased its position in shares of AngioDynamics by 2.8% in the first quarter. Prudential Financial Inc. now owns 62,871 shares of the company’s stock valued at $773,000 after buying an additional 1,700 shares during the period. BlackRock Fund Advisors increased its position in shares of AngioDynamics by 1.0% in the first quarter. BlackRock Fund Advisors now owns 1,690,166 shares of the company’s stock valued at $20,772,000 after buying an additional 16,287 shares during the period. JPMorgan Chase & Co. acquired a new position in shares of AngioDynamics during the first quarter valued at $3,552,000. Acrospire Investment Management LLC acquired a new position in shares of AngioDynamics during the first quarter valued at $305,000. Finally, Royce & Associates LP increased its position in shares of AngioDynamics by 12.5% in the first quarter. Royce & Associates LP now owns 720,801 shares of the company’s stock valued at $8,859,000 after buying an additional 80,000 shares during the period. 69.29% of the stock is owned by hedge funds and other institutional investors.
In other news, Director David F. Burgstahler sold 2,250,000 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,895,000.00. Following the completion of the transaction, the director now directly owns 23,988 shares of the company’s stock, valued at approximately $350,704.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The disclosure for this sale can be found here. 1.88% of the stock is owned by insiders.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Stock Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related stocks with our FREE daily email newsletter.